Cargando…
Metabolic effects of pamidronate in patients with metastatic bone disease.
We have evaluated the value of specific bone resorption markers in monitoring metastatic bone disease to define the duration of action of a single high-dose pamidronate infusion. Twenty patients received a single infusion of pamidronate 120 mg for painful bone metastases. Ten out of these 20 patient...
Autores principales: | Vinholes, J., Guo, C. Y., Purohit, O. P., Eastell, R., Coleman, R. E. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074415/ https://www.ncbi.nlm.nih.gov/pubmed/8624269 |
Ejemplares similares
-
High-dose intravenous pamidronate for metastatic bone pain.
por: Purohit, O. P., et al.
Publicado: (1994) -
A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
por: Purohit, O. P., et al.
Publicado: (1995) -
Analgesia and curative effect of pamidronate disodium combined with chemotherapy on elderly patients with advanced metastatic bone cancer
por: Liu, Jiayong, et al.
Publicado: (2019) -
Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment
por: Spirlandeli, Adriano L., et al.
Publicado: (2017) -
Bone resorption predicts for skeletal complications in metastatic bone disease
por: Brown, J E, et al.
Publicado: (2003)